Improved Limits on B0B^{0} decays to invisible (+γ)(+\gamma) final states

We establish improved upper limits on branching fractions for B0 decays to final States 10 where the decay products are purely invisible (i.e., no observable final state particles) and for final states where the only visible product is a photon. Within the Standard Model, these decays have branching fractions that are below the current experimental sensitivity, but various models of physics beyond the Standard Model predict significant contributions for these channels. Using 471 million BB pairs collected at the Y(4S) resonance by the BABAR experiment at the PEP-II e+e- storage ring at the SLAC National Accelerator Laboratory, we establish upper limits at the 90% confidence level of 2.4x10^-5 for the branching fraction of B0-->Invisible and 1.7x10^-5 for the branching fraction of B0-->Invisible+gammaComment: 8 pages, 3 postscript figures, submitted to Phys. Rev. D (Rapid Communications

Calculation of wing response to gusts and blast waves with vortex lift effect

A numerical study of the response of aircraft wings to atmospheric gusts and to nuclear explosions when flying at subsonic speeds is presented. The method is based upon unsteady quasi-vortex-lattice method, unsteady suction analogy, and Pade approximate. The calculated results, showing vortex lag effect, yield reasonable agreement with experimental data for incremental lift on wings in gust penetration and due to nuclear blast waves

Calculation of wing response to gusts and blast waves with vortex lift effect

A numerical study of the response of aircraft wings to atmospheric gusts and to nuclear explosions when flying at subsonic speeds is presented. The method is based upon unsteady quasi-vortex lattice method, unsteady suction analogy and Pade approximant. The calculated results, showing vortex lag effect, yield reasonable agreement with experimental data for incremental lift on wings in gust penetration and due to nuclear blast waves

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC. We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level of 5% or more. Among the 423 patients with a PD-L1 expression level of 5% or more, the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy (hazard ratio for disease progression or death, 1.15; 95% confidence interval [CI], 0.91 to 1.45; P=0.25), and the median overall survival was 14.4 months versus 13.2 months (hazard ratio for death, 1.02; 95% CI, 0.80 to 1.30). A total of 128 of 212 patients (60%) in the chemotherapy group received nivolumab as subsequent therapy. Treatment-related adverse events of any grade occurred in 71% of the patients who received nivolumab and in 92% of those who received chemotherapy. Treatment-related adverse events of grade 3 or 4 occurred in 18% of the patients who received nivolumab and in 51% of those who received chemotherapy. Nivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD-L1 expression level of 5% or more. Overall survival was similar between groups. Nivolumab had a favorable safety profile, as compared with chemotherapy, with no new or unexpected safety signals. (Funded by Bristol-Myers Squibb and others; CheckMate 026 ClinicalTrials.gov number, NCT02041533 .)

Dependence of the energy resolution of a scintillating crystal on the readout integration time

The possibilty of performing high-rate calorimetry with a slow scintillating crystal is studied. In this experimental situation, to avoid pulse pile-up, it can be necessary to base the energy measurement on only a fraction of the emitted light, thus spoiling the energy resolution. This effect was experimentally studied with a BGO crystal and a photomultiplier followed by an integrator, by measuring the maximum amplitude of the signals. The experimental data show that the energy resolution is exclusively due to the statistical fluctuations of the number of photoelectrons contributing to the maximum amplitude. When such number is small its fluctuations are even smaller than those predicted by Poisson statistics. These results were confirmed by a Monte Carlo simulation which allows to estimate, in a general case, the energy resolution, given the total number of photoelectrons, the scintillation time and the integration time

Exclusive Measurements of b -> s gamma Transition Rate and Photon Energy Spectrum

We use 429 fb$^{-1}$ of $e^+e^-$ collision data collected at the $\Upsilon(4S)$ resonance with the BABAR detector to measure the radiative transition rate of $b\rightarrow s\gamma$ with a sum of 38 exclusive final states. The inclusive branching fraction with a minimum photon energy of 1.9 GeV is found to be $\mathcal{B}(\bar B \rightarrow X_{s}\gamma)=(3.29\pm 0.19\pm 0.48)\times 10^{-4}$ where the first uncertainty is statistical and the second is systematic. We also measure the first and second moments of the photon energy spectrum and extract the best fit values for the heavy-quark parameters, $m_{b}$ and $\mu_{\pi}^{2}$, in the kinetic and shape function models.Comment: 18 pages, 14 pdf figures, submitted to Phys. Rev.

b --> s g g decay in the two and three Higgs doublet models with CP violating effects

We study the decay width and CP-asymmetry of the inclusive process b--> s g g (g denotes gluon) in the three and two Higgs doublet models with complex Yukawa couplings. We analyse the dependencies of the differential decay width and CP-asymmetry to the s- quark energy E_s and CP violating parameter \theta. We observe that there exist a considerable enhancement in the decay width and CP asymmetry is at the order of 10^{-2}. Further, it is possible to predict the sign of C_7^{eff} using the CP asymmetry.Comment: 15 pages, 7 Figures (required epsf style